Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued PatentsGlobeNewswire
- Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024GlobeNewswire
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswire
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsGlobeNewswire
- Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual MeetingGlobeNewswire
OBIO
Analyst Actions
- 3/28/24 - Chardan Capital